Research involving tirzepatide expanded significantly following phase 2 and phase 3 clinical trial findings involving obesity and type 2 diabetes
J Neuroinflammation 16(1):242 Sheahan KH, Wahlberg EA, Gilbert MP (2020) An overview of GLP-1 agonists and recent cardiovascular outcomes trials
This helps your body adjust to the medication and reduces nausea
It produced slightly higher average weight loss in trials, and semaglutide carries years of safety and outcome data across its injectable and oral forms
[1] Commonly prescribed GLP-1 agonists include semaglutide (Ozempic for diabetes, Wegovy for weight management), dulaglutide (Trulicity), liraglutide (Victoza for diabetes, Saxenda for weight management), and exenatide (Byetta, Bydureon)
These improvements contribute not only to weight loss but also to better overall health